Leotta et al. 1 recently reported rapid stem cell mobilization with plerixafor after failure of marrow harvest. We report a case of a 50-year-old woman, who was chosen as a sibling donor for PBSCs in an allogeneic transplantation. Standard evaluation procedure before stem cell mobilization showed no contraindication against donation. Her 46-yearold brother suffered from high-risk multiple myeloma and was scheduled for allo-SCT after conditioning with melphalan/fludarabine/alemtuzumab. 2 We started mobilization with G-CSF in a dosage of 5 mg/kg s.c. two times a day, 5 days before leukapheresis.
3 CD34 þ cell count in blood was determined by flow cytometry. 4 At time of first leukapheresis, we found insufficient mobilization of CD34 þ stem cells into the peripheral blood; the CD34 count was 14 cells per mL with total leukocytes of 21.6 Gpt/L. Concurrently, during the first leukapheresis, we were unable to collect a sufficient amount of CD34 þ stem cells; the apheresis yielded only 23.9 Â 10 6 CD34 þ cells, equivalent to 0.32 Â 10 6 CD34 þ cells per kg body weight of the recipient.
In spite of continued application of G-CSF, the CD34 þ cell count in the peripheral blood decreased to 4 cells per mL and 3 cells per mL during the next 2 days; hence, we had to accept that we were unable to mobilize an adequate number of CD34 þ stem cells with G-CSF alone. A conventional BM harvest was refused by the donor. Initiation of a search for an unrelated donor was not an option as the conditioning of the recipient was completed. The harvested stem cells were transplanted.
As a consequence, we discussed a combined mobilization with G-CSF and plerixafor before a second leukapheresis to increase the stem cell yield. 5, 6 Despite the experimental nature of this approach and possible unknown long-term side effects of plerixafor, the donor agreed after detailed counseling and explanation of the risks involved in the planned procedure. After 6 days of ongoing stimulation with G-CSF, we added plerixafor in a recommended dose of 0.24 mg/kg body weight per day by s.c. injection, starting on the evening before the planned leukapheresis. Over the next few days, the CD34 þ cell count in the peripheral blood increased to 32 cells per mL and 21 cells per mL. The peripheral CD34 cell count increased satisfactorily under plerixafor despite falling counts with ongoing G-CSF alone (Figure 1) . The leukapheresis performed 2 days after initiation of plerixafor yielded 113.9 Â 10 6 and 83.6 Â 10 6 CD34 þ cells, equivalent to 1.50 Â 10 6 and 1.09 Â 10 6 CD34 þ cells per kg body weight of the recipient (Figure 1) .
In the end, the addition of plerixafor to the ongoing stimulation with G-CSF enabled us to collect an adequate number of CD34 þ cells (total 2.9 Â 10 6 CD34 þ cells per kg body weight of the recipient) for allogeneic transplantation. The recipient did well and engrafted in time (leukocyte count 41.0 giga particles per litre (Gpt/L) on day þ 13 and thrombocytes 420 Gpt/L on day þ 16). The patient was discharged on day þ 35. At last follow-up on day þ 263, the myeloma was in CR, the donor chimerism in the marrow was 98% and the patient was doing well.
The application of plerixafor in a healthy donor is an offlabel use of this medication, as plerixafor is only approved for autologous stem cell mobilization in patients with multiple myeloma or non-Hodgkin's lymphoma. However, there was no reasonable alternative in the reported case in order to avoid primary graft failure or prolonged neutropenia. The donor's follow-up is actually 8 months. So far, the donor has not experienced serious side effects; only mild and transient hypokalemia and hypocalcemia during leukapheresis (not attributable to plerixafor) have been observed. The blood smear normalized within 3 days after apheresis. Further periodic visits by the donor were arranged to register possible long-term side effects of plerixafor. Although we obviously can not recommend this as a standard approach in case of G-CSF failure, the addition of plerixafor to an ongoing stimulation with G-CSF may be considered as a rescue procedure in healthy related donors ineligible for conventional BM harvest after informed consent. Further investigations are necessary to confirm the long-term safety of plerixafor in volunteer donors.
